James P Luyendyk Selected Research

Carcinogenesis

3/2016	Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis.
10/2013	Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.
9/2007	COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James P Luyendyk Research Topics

Disease

37	Inflammation (Inflammations) 01/2023 - 10/2003
17	Liver Diseases (Liver Disease) 11/2023 - 12/2010
16	Necrosis 01/2024 - 09/2005
12	Fibrosis (Cirrhosis) 11/2021 - 03/2012
10	Liver Cirrhosis (Hepatic Cirrhosis) 11/2021 - 12/2010
9	Acute Liver Failure (Fulminant Hepatic Failure) 01/2024 - 10/2007
8	Hemorrhage 01/2024 - 05/2010
8	Thrombosis (Thrombus) 01/2022 - 03/2006
8	Non-alcoholic Fatty Liver Disease 12/2016 - 06/2006
7	Fatty Liver 08/2017 - 01/2010
7	Cholestasis 01/2017 - 04/2009
6	Neoplasms (Cancer) 11/2023 - 11/2008
6	Hypoxia (Hypoxemia) 08/2011 - 07/2004
4	Obesity 12/2022 - 10/2012
4	Afibrinogenemia (Fibrinogen Deficiency) 12/2022 - 03/2011
3	Body Weight (Weight, Body) 12/2016 - 07/2014
3	Carcinogenesis 03/2016 - 09/2007
2	Liver Failure 12/2023 - 01/2023
2	Peritonitis 01/2022 - 01/2022
2	Endotoxemia 01/2022 - 07/2008
2	Infections 01/2019 - 03/2013
2	Hyperplasia 01/2016 - 01/2016
2	Hypercholesterolemia 02/2012 - 01/2009
2	Drug-Related Side Effects and Adverse Reactions 04/2006 - 10/2003
1	Vascular System Injuries 01/2024
1	Adenocarcinoma 11/2023
1	Disease Progression 11/2023
1	Acute-Phase Reaction 01/2022
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022
1	Wounds and Injuries (Trauma) 01/2019

Drug/Important Bio-Agent (IBA)

24	FibrinIBA 11/2023 - 07/2004
14	Hemostatics (Antihemorrhagics)IBA 01/2023 - 03/2006
12	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2024 - 10/2007
11	Thromboplastin (Tissue Factor)IBA 06/2015 - 05/2006
10	Fibrinogen (Factor I)FDA Link 11/2023 - 03/2011
10	estropipate (Ogen)FDA LinkGeneric 11/2023 - 01/2011
10	Proteins (Proteins, Gene)FDA Link 11/2021 - 05/2010
10	Thrombin FDA Link 01/2018 - 01/2010
8	Peptide Hydrolases (Proteases)FDA Link 11/2023 - 01/2010
8	1-Naphthylisothiocyanate (1 Naphthylisothiocyanate)IBA 11/2021 - 04/2009
7	CytokinesIBA 11/2023 - 11/2013
7	Bile Acids and Salts (Bile Acids)IBA 03/2016 - 03/2011
7	LipopolysaccharidesIBA 11/2010 - 10/2003
6	XenobioticsIBA 01/2017 - 10/2003
6	Alanine Transaminase (SGPT)IBA 03/2011 - 03/2006
5	Biomarkers (Surrogate Marker)IBA 01/2024 - 03/2006
5	Messenger RNA (mRNA)IBA 01/2017 - 12/2010
4	Blood Coagulation Factors (Coagulation Factor)IBA 11/2023 - 05/2014
4	Plasminogen Activator Inhibitor 1IBA 01/2018 - 07/2004
4	Plasminogen Activators (Plasminogen Activator)IBA 01/2018 - 03/2006
4	AntithrombinsIBA 08/2017 - 10/2012
4	Thrombin Receptors (Thrombin Receptor)IBA 12/2016 - 01/2010
4	IntegrinsIBA 01/2016 - 12/2010
3	von Willebrand FactorIBA 11/2021 - 01/2017
3	Carbon Tetrachloride (Tetrachloromethane)IBA 11/2021 - 01/2017
3	Dabigatran FDA Link 08/2017 - 11/2014
3	Interleukin-6 (Interleukin 6)IBA 12/2016 - 03/2006
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 08/2013 - 12/2010
3	Ranitidine (Zantac)FDA LinkGeneric 08/2007 - 07/2004
2	TransglutaminasesIBA 11/2023 - 01/2016
2	PlasminogenIBA 11/2023 - 01/2022
2	Fibrinolysin FDA Link 11/2023 - 01/2021
2	Antifibrinolytic Agents (Antifibrinolytics)IBA 11/2023 - 06/2014
2	Small Interfering RNA (siRNA)IBA 01/2022 - 12/2017
2	EnzymesIBA 01/2021 - 06/2010
2	AnticoagulantsIBA 01/2021 - 06/2016
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2018 - 06/2012
2	Folic Acid (Vitamin M)FDA LinkGeneric 12/2017 - 01/2016
2	Trichloroethylene (Trichloroethene)IBA 01/2017 - 10/2014
2	Clopidogrel (Plavix)FDA Link 01/2016 - 05/2010
2	ApolipoproteinsIBA 07/2014 - 06/2010
2	Transcription Factors (Transcription Factor)IBA 03/2012 - 08/2011
2	oxidized low density lipoproteinIBA 02/2012 - 06/2010
2	LDL Receptors (LDL Receptor)IBA 11/2011 - 01/2009
2	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2011 - 12/2010
2	Choline (Choline Chloride)IBA 12/2010 - 01/2010
2	Methionine (L-Methionine)FDA Link 12/2010 - 01/2010
2	Metformin (Glucophage)FDA LinkGeneric 06/2006 - 03/2006
2	Aflatoxin B1 (Aflatoxin B)IBA 03/2003 - 07/2002
1	Factor XIII (Coagulation Factor XIII)IBA 11/2023
1	Interleukin-10 (Interleukin 10)IBA 01/2023
1	PolymersIBA 12/2022
1	fibrin fragment D (D-dimer)IBA 01/2022
1	DisintegrinsIBA 01/2021
1	ThrombospondinsIBA 01/2021
1	Metalloproteases (Metalloproteinases)IBA 01/2021
1	High-Molecular-Weight Kininogen (Kininogen, High Molecular Weight)IBA 01/2021
1	Proteinase-Activated ReceptorsIBA 07/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2019
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2018
1	Factor Xa (Coagulation Factor Xa)IBA 01/2018
1	CaspasesIBA 01/2018
1	Mitogen-Activated Protein KinasesIBA 12/2017
1	Glycoproteins (Glycoprotein)IBA 12/2017
1	Phospholipases (Phospholipase)IBA 12/2017
1	ThrombomodulinIBA 08/2017

Therapy/Procedure

4	Therapeutics 01/2021 - 11/2008
1	Hepatectomy 11/2023
1	Lasers (Laser) 01/2022
1	Investigational Therapies (Experimental Therapy) 01/2021